Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X about a paper by Justin Z. Wang et al. published in Nature Medicine:
“Study published in Nature Medicine highlights the potential for molecular profiling to refine surgical and radiotherapy decision-making. Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma.”
Title: Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma
Authors: Justin Z. Wang, Vikas Patil, Alexander P. Landry, Chloe Gui, Andrew Ajisebutu, Jeff Liu, Olli Saarela, Stephanie L. Pugh, Minhee Won, Zeel Patel, Rebeca Yakubov, Ramneet Kaloti, Christopher Wilson, Aaron Cohen-Gadol, Mohamed A. Zaazoue, Ghazaleh Tabatabai, Marcos Tatagiba, Felix Behling, Damian A. Almiron Bonnin, Eric C. Holland, Tim J. Kruser, Jill S. Barnholtz-Sloan, Andrew E. Sloan, Craig Horbinski, Silky Chotai, Lola B. Chambless, Andrew Gao, Alexander D. Rebchuk, Serge Makarenko, Stephen Yip, Felix Sahm, Sybren L. N. Maas, Derek S. Tsang, The International Consortium on Meningiomas (ICOM), C. Leland Rogers, Kenneth Aldape, Farshad Nassiri, Gelareh Zadeh
You can read the Full Article in Nature Medicine.
More posts featuring Vivek Subbiah.